One month later, Dundee Cancer Center announced a new way to kill cancer cells in people with one of the most common forms of leukemia. Another Scottish company transforming the future treatment of cancer is VIRTTU, the first company allowed by the FDA to trial an oncolytic therapy in children, who has announced plans to assist in an upcoming pediatric brain tumor trial led by Cincinnati Children's Hospital.
Other Scottish organizations making developments include the University of Aberdeen, which was awarded $2 million in funding this February to research anti-cancer drugs utilizing shark immune system research and The University of Edinburgh, which received $26 million this month to research regenerative medicine for incurable conditions.
Scotland's recent R&D achievements have occurred alongside major company growth as well. Edinburgh BioQuarter, part of Europe's fastest-growing academic medical center, grew by more than a third in January alone thanks to new research tenants. Just this month, U.S. medical device company Daktari Diagnostics Inc. announced their decision to invest in Scotland to produce its latest HIV blood monitoring technology.
"Scotland's life science legacy boasts innovations such as the pioneering of stem-cell treatments to cure blindness and groundbreaking work to eradicate disease-carrying tsetse flies," says Cusick. "With this reputation for excellence, we feel confident that our recent R&D announcements will spur positive investment."
Home to 650+ life sciences organizations and more than 32,000 industry employees, Scotland seeks to target additional partnership and investment opportunities from North America to bolster their rapidly growing industry.
|SOURCE Scottish Development International|
Copyright©2012 PR Newswire.
All rights reserved